Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

59.70
+0.11000.18%
Post-market: 59.67-0.0300-0.05%18:08 EDT
Volume:11.09M
Turnover:662.02M
Market Cap:121.53B
PE:13.14
High:60.10
Open:59.45
Low:59.01
Close:59.59
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.84
T/O Rate:0.55%
Dividend:2.51
Dividend Rate:4.20%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.45
PE(LYR):17.25

Loading ...

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

Perspective Therapeutics [212Pb]VMT01 Melanoma Trial Data Set for SITC 2026 Presentation

Reuters
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

Bristol Myers Squibb Co. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

BMY Terminates Early Leukemia Trial, Trimming One Risky Bet From Its Oncology Pipeline

TIPRANKS
·
Oct 02

InflaRx Appoints Gabriela Alperovich as SVP, Global Head of Clinical Development

Reuters
·
Oct 01

Iovance Biotherapeutics Names Noah Berkowitz Chief Medical Officer

Reuters
·
Oct 01

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

THOMSON REUTERS
·
Oct 01

Sanofi’s Regeneron Fix Requires Extra Shot of M&A

Reuters
·
Oct 01

Bayer Names Christoph Koenen Chief Medical Officer

Reuters
·
Oct 01

Faron Pharmaceuticals Doses First Patient in Phase 1/2 BLAZE Trial of Bexmarilimab Plus Bristol Myers’ Opdivo in PD-1-Resistant Solid Tumors

Reuters
·
Oct 01

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos® (Mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm) in Adults and Pediatric Patients*

THOMSON REUTERS
·
Oct 01

Bristol-Myers Squibb's Camzyos to Treat Heart Condition Receives FDA Approval for Pediatric Patients

MT Newswires Live
·
Oct 01

FDA: Approved Camzyos (Mavacamten) Capsules as First Treatment for Children with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Website

THOMSON REUTERS
·
Oct 01

FDA Approves First Drug to Improve Functional Capacity and Symptoms in Children with Rare Inherited Heart Condition

THOMSON REUTERS
·
Oct 01

FDA: Camzyos Carries Boxed Warning for Heart Failure Risk, Restricted to Rems Program

THOMSON REUTERS
·
Oct 01

FDA approves Bristol Myers’ Camzyos capsules for children with oHCM

TIPRANKS
·
Oct 01

Bristol-Myers' Protocol Changes Add Risk, Keep Admilparant on Track, UBS Says

MT Newswires Live
·
Oct 01